Perhimpunan Dokter Paru Indonesia - Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival
Free Web Counters
Mitra Kerja
Tutorial Aplikasi ISR
Uploaded on May 11, 2015
World Asthma Day 2018
Uploaded on Apr 30, 2018


Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival

penyakit paru
image: pancare.org

Hela Cherif1, Saoussen Bacha1, Sonia Habibech1, Hager Racil1, Sana Cheikhrouhou1, Naouel Chaouech1, Abdellatif Chabbou1 and Mohamed Lamine Megdiche1
1Pulmonary Medicine, Abderrahmane Mami Hospital, Ariana, Tunisia

Introduction: Cytotoxic chemotherapy is widely used to palliate advanced non-small-cell lung cancer (NSCLC) but can induce severe toxic events. The aim of this study was to evaluate the chemotherapy toxicity in adavanced non-small cell lung cancer (NSCLC) and its impact on overall survival (OS).

Methods: We retrospectively reviewed 99 advanced stage NSCLC patients treated with chemotherapy over a period of 3 years. Pre-therapeutic clinical and biological data were assessed. OS was calculated using the Kaplan Meier method and compared between two groups (having or not toxicity) by log rank test.

Results: Median age was 65 years, 84% of patients had Performans status (PS) <2, 28% were malnourished (BMI <20 kg/m2). Anemia (Hb<12g/dL) and hypoalbuminemia were observed respectively in 30% and 10% of cases. Platinum chemotherapy regimen was used in 86% of cases. Seventy-eight percent of the patients has developed at least one chemotherapy related toxic event. Main toxicities were hematologic (47%; 26% of toxicity≥ grade 3), gastrointestinal (30%; 58% of toxicity ≥ grade 3) and renal (20%; 9% of toxicity ≥ grade 3). Eighty-five percent of toxic events occurred at the first line and on average over 1.7 th cycle. No toxic death event has happened. Patients with PS ≤2, anemia, malnutrition and hypoalbuminemia didn't developed more chemotherapy-induced toxicity (p=0.66; p =0.48; p=0.93; p=0.78 respectively). OS of patients with chemotherapy toxic event was 12.3 months compared with 7.51 months in patients without chemotherapy toxic event (logrank; p = 0.002).

Conclusion: Our study suggested that Chemotherapy-induced toxicity in advanced NSCLC patients was associated with poor survival.

Source : http://erj.ersjournals.com/content/48/suppl_60/PA4841
Image : https://www.pancare.org.au/...

PDPI Jatim. 09/09/17.

Halaman Siap Cetak  Halaman Siap Cetak

Kirimkan Pada Rekan  Kirimkan Pada Rekan